Dr. Frederic Bard is making waves in Singapore’s biotherapeutics space as scientific founder and CEO of startup Albatroz Therapeutics, which secured $3M USD in seed funding earlier this year.
Fred, as his colleagues call him, kickstarted this journey at IMCB, where he worked on the groundbreaking technology behind Albatroz for more than a decade. It was here where he first characterized the role of the GalNAc-T Activation (GALA) glycosylation pathway in driving extracellular matrix (ECM) degradation – a process that spurs tumor growth and spread, as well as arthritis progression. This discovery led to the uncovering of a new therapeutic target, which Fred and his team found a way to attack using antibodies, potentially yielding new treatments for cancer and arthritis.